Skip to main content
Premium Trial:

Request an Annual Quote

Amarantus Inks Research Collaboration with BU to Evaluate LymPro Test as CTE, Alzheimer's Dx


Amarantus Bioscience this week said that it has established a research collaboration with Boston University School of Medicine to evaluate its blood-based protein biomarker LymPro Test for identifying early stage sufferers of neurodegenerative diseases, chronic traumatic encephalopathy, and Alzheimer's disease.

The company will work with Robert Stern, BUSM professor of neurology and neurosurgery and clinical core director at the BU Alzheimer's Disease Center. Stern is currently involved in a National Institutes of Health-funded study looking at methods of detecting CTE.

"We are pleased to be establishing this collaboration to evaluate the potential of LymPro in this emerging area of medical interest," Gerald Commissiong, president and CEO of Amarantus, said in a statement. "While the research is early in nature, there is a strong scientific basis to believe that the cell cycle dysregulation that LymPro measures in Alzheimer's patients may have relevance to traumatic brain injury and CTE."

Financial and other terms of the collaboration were not disclosed.